Understanding PDA Technical Report 26: Sterilizing Filtration of Liquids

The most direct and recommended method is to purchase the PDF from an official source. This guarantees you receive the authentic, complete, and latest version of the report.

PDA TR 26 aligns tightly with international regulatory updates, including:

PDA Technical Report No. 26, titled is one of the pharmaceutical industry's most widely cited and essential reference documents. Its primary purpose is to provide comprehensive guidance on the use and validation of sterilizing filtration processes , which are critical for ensuring the sterility of many pharmaceutical and biotechnological products.

Used primarily for hydrophobic venting filters. 4. Validation and Risk Management

First published in 1998 and significantly revised in 2008, PDA Technical Report No. 26 serves as a global industry benchmark. It bridges the gap between regulatory expectations—such as those from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—and practical manufacturing operations.

: The full document can be purchased from the PDA Bookstore .

The document bridges scientific principles with strict regulatory requirements. It focuses extensively on several key areas of sterile manufacturing: 1. Filter Selection and Characterization

If the purchase price is a barrier, consider these legitimate alternatives for accessing the report:

This is the most critical aspect of TR 26. Regulatory bodies require proof that a filter can successfully eliminate microbes under worst-case processing conditions. TR 26 outlines the methodology for the standard bacterial challenge test using Brevundimonas diminuta (ATCC 19146) at a minimum challenge level of 10710 to the seventh power

PDA Technical Report No. 26 (TR 26), titled , is a primary resource for pharmaceutical professionals on the selection, validation, and operation of liquid filtration systems. While the full document is proprietary and typically requires purchase, several official and expert resources provide detailed summaries and access instructions. How to Access PDA Technical Report 26

: Current PDA Members can view the entire library of active reports, including TR 26, for free online.

The 2025 revision addresses the need for stronger, proactive risk management in pharmaceutical manufacturing, aligning with modern "quality by design" (QbD) principles. 1. Shift Toward Proactive Risk Control

, it remains the authoritative source for regulatory compliance. Parenteral Drug Association

The filtration process must be validated under conditions that simulate worst-case scenarios, including maximum pressure, temperature, and duration of filtration.